- Home
- BANF vs SCLXW Comparison
BANF vs SCLXW Comparison
Compare BANF & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANF
- SCLXW
- Stock Information
- Founded
- BANF 1984
- SCLXW N/A
- Country
- BANF United States
- SCLXW United States
- Employees
- BANF N/A
- SCLXW 113
- Industry
- BANF Major Banks
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- BANF Finance
- SCLXW Health Care
- Exchange
- BANF Nasdaq
- SCLXW Nasdaq
- Market Cap
- BANF N/A
- SCLXW N/A
- IPO Year
- BANF N/A
- SCLXW 2021
- Fundamental
- Price
- BANF $119.75
- SCLXW $0.24
- Analyst Decision
- BANF Hold
- SCLXW
- Analyst Count
- BANF 3
- SCLXW 0
- Target Price
- BANF $113.33
- SCLXW N/A
- AVG Volume (30 Days)
- BANF 112.9K
- SCLXW N/A
- Earning Date
- BANF 01-28-2025
- SCLXW N/A
- Dividend Yield
- BANF 1.54%
- SCLXW N/A
- EPS Growth
- BANF N/A
- SCLXW N/A
- EPS
- BANF 6.22
- SCLXW N/A
- Revenue
- BANF $608,332,000.00
- SCLXW N/A
- Revenue This Year
- BANF N/A
- SCLXW N/A
- Revenue Next Year
- BANF $2.89
- SCLXW N/A
- P/E Ratio
- BANF $19.25
- SCLXW N/A
- Revenue Growth
- BANF N/A
- SCLXW N/A
- 52 Week Low
- BANF $81.21
- SCLXW N/A
- 52 Week High
- BANF $132.29
- SCLXW N/A
- Technical
- Relative Strength Index (RSI)
- BANF 52.93
- SCLXW N/A
- Support Level
- BANF $116.33
- SCLXW N/A
- Resistance Level
- BANF $119.95
- SCLXW N/A
- Average True Range (ATR)
- BANF 3.22
- SCLXW 0.00
- MACD
- BANF 0.38
- SCLXW 0.00
- Stochastic Oscillator
- BANF 86.71
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.